// App-Quantinova.ai

GS3-03 : KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery

Researchers

Presenter

  • Peter Schmid

Principal Investigators

  • Marta Ferreira

  • Marie-Ange Mouret-Reynier

  • Seock-Ah Im

  • Jin-Hee Ahn

  • Maria Gion

  • Rina Hui

  • Sally Baron-Hay

  • Jean-Francois Boileau

  • Mei-Ching Liu

  • Nadia Harbeck

  • Masato Takahashi

  • Theodoros Foukakis

  • Peter A Fasching

  • Fatima Cardoso

  • Jay Andersen

  • Michael Untch

  • Margarita Tokar

  • Florence Dalenc

  • Michael Danso

  • Debra Patt

  • Sherko Kmmel

  • Carsten Denkert

  • Lajos Pusztai

  • Jonas Bergh

  • Heather McArthur

  • Liyi Jia

  • Gursel Aktan

  • Vassiliki Karantza

  • Rebecca Dent

  • Javier Cortes

  • Joyce OShaughnessy

Medical Centers

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

  • Centre Jean Perrin, Clermont-Ferrand, France

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Surgery, , Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

  • Ramon y Cajal University Hospital, Madrid, Spain

  • Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, NSW, Australia

  • Royal North Shore Hospital, Sydney, Australia

  • McGill University, Jewish General Segal Cancer Centre, Montreal, QC, Canada

  • Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan

  • Breast Center, University of Munich, Munich, Germany

  • Hokkaido Cancer Center, Sapporo, Japan

  • Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, Sweden

  • University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany

  • Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal

  • Compass Oncology, US Oncology, Portland, OR

  • Breast Cancer Center, Helios Klinikum Berlin Buch, Berlin, Germany

  • Soroka University Medical Center/Ben-Gurion University of the Negev, Beer Sheva, Israel

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Virginia Oncology Associates, Norfolk, VA

  • Texas Oncology, Austin, TX

  • AGO & Kliniken Essen Mitte, Essen, Germany

  • Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Merck and Co., Rahway, NJ

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Toronto, Toronto, ON, Canada

  • IOB Institute of Oncology, Quiron Group; Vall d'Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain

  • Texas Oncology, Dallas, TX

Locations

  • United Kingdom

  • Republic of South Korea

  • Portugal

  • France

  • Spain

  • Australia

  • Canada

  • China

  • Germany

  • Japan

  • Sweden

  • United States

  • Israel

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03036488

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved